Mizuho Initiates Coverage On Cartesian Therapeutics with Buy Rating, Announces Price Target of $40
Portfolio Pulse from Benzinga Newsdesk
Mizuho has initiated coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Buy rating and set a price target of $40.
May 24, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho has initiated coverage on Cartesian Therapeutics with a Buy rating and set a price target of $40.
The initiation of coverage with a Buy rating and a specific price target of $40 by a reputable analyst from Mizuho is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100